FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Highlight the role of humanin and MOTS-c in aging processes and their potential as therapeutic targets for age-related diseases.
Retour à la bibliothèque de recherche
humaninMOTS-c

Highlight the role of humanin and MOTS-c in aging processes and their potential as therapeutic targets for age-related diseases.

May 17, 2026
Share

Papier source

Mitochondrial-derived peptides in aging and age-related diseases.

Kim Su-Jeong et al.GeroScience2021
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article décompose les résultats du papier source ci-dessus dans un langage accessible pour la communauté de recherche en peptides. Notre objectif est d'highlighter ce qui compte le plus — les implications pratiques, la force des preuves et ce que cela signifie pour la recherche en cours.

Mitochondrial Messengers: Humanin and MOTS-c in Aging and Disease

Published: May 17, 2026 | Source: GeroScience (2021) | Category: humanin, MOTS-c

Overview

A recent review published in GeroScience highlights the critical role of mitochondrial-derived peptides, specifically humanin and MOTS-c, in aging processes such as cellular senescence, chronic inflammation, and cognitive decline. This research suggests that these peptides may serve as potential therapeutic targets for age-related diseases.

Study Background

As we age, our mitochondria—the powerhouses within cells—become less efficient, leading to a range of health issues from muscle weakness to neurodegeneration. Previous studies have linked mitochondrial dysfunction with aging and age-related diseases, but the specific mechanisms remain unclear. The review by Kim et al. focuses on mitochondrial-derived peptides (MDPs) like humanin and MOTS-c, which are small molecules produced within mitochondria that play a role in cellular health.

What the Research Found

The study synthesizes existing literature to demonstrate how MDPs contribute to aging processes:

  • Humanin: This peptide is known for its anti-apoptotic (anti-cell death) properties and has been shown to protect cells from oxidative stress. It plays a significant role in reducing cellular senescence, which is the process by which cells lose their ability to divide.
  • MOTS-c: Another MDP, MOTS-c, regulates metabolism and inflammation. Studies have linked it with improved insulin sensitivity and reduced chronic inflammation, both of which are crucial for aging healthily.

The review also discusses genetic variations in humanin and MOTS-c that are associated with age-related diseases such as Alzheimer's disease and type 2 diabetes. These variations can affect the expression levels of MDPs, thereby influencing age-related phenotypes.

What This Means for Peptide Users

While this research highlights the potential therapeutic value of humanin and MOTS-c in combating aging processes, it is important to note that these peptides are still under investigation. For peptide users, understanding the role of MDPs can provide insights into how mitochondrial health impacts overall cellular function and longevity.

Limitations and Caveats

As a review paper, this study relies heavily on existing literature rather than presenting new experimental data. This means it may not capture all recent findings or emerging research in the field. Additionally, while the potential therapeutic benefits of MDPs are promising, further clinical trials are necessary to confirm their efficacy and safety.

How This Compares to Previous Research

The review builds upon earlier studies that have individually examined humanin and MOTS-c but integrates them into a broader context of aging and age-related diseases. It aligns with other research suggesting the importance of mitochondrial health in cellular aging, yet it also highlights gaps in our understanding of how genetic variations influence MDP expression.

Our Analysis

PeptideVault's analysis suggests that while this review provides valuable insights into the role of humanin and MOTS-c in aging processes, more experimental data is needed to fully understand their therapeutic potential. The study effectively synthesizes existing knowledge but does not introduce new findings or methodologies.

Key Takeaways

  • Humanin and MOTS-c play crucial roles in protecting cells from damage and regulating metabolic health.
  • Genetic variations affect MDP levels, which can influence the development of age-related diseases.
  • Further research is needed to confirm the therapeutic potential of these peptides.

Original Source

Citation: Kim Su-Jeong, Miller Brendan, Kumagai Hiroshi et al. (2021). Mitochondrial-derived peptides in aging and age-related diseases.. GeroScience. DOI: 10.1007/s11357-020-00262-5

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été préparée par l'équipe de recherche de Peptide Contacts. Nous encourageons les lecteurs à vérifier les informations auprès du papier source complet pour la méthodologie et les données complètes. L'original de la publication est disponible sur le PubMed.

Recherches connexes

Comments

Sign in to join the discussion

Cette analyse est générée à partir d'une recherche peer-reviewed pour des fins éducatives uniquement. Elle ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.